However, several clinical trials explore the inhibition of the PI3K/AKT/mTOR pathway, which is commonly altered in TNBC or in resistant ER+ or HER2+ breast cancer subtypes [203,204,205]. This evidence concerns the gene ESR1 and breast carcinoma.